The remarkable impact of bivalent HPV vaccine in Scotland
- PMID: 30944088
- DOI: 10.1136/bmj.l1375
The remarkable impact of bivalent HPV vaccine in Scotland
Conflict of interest statement
Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: JMLB’s employer has received partial, unrestricted support (in the form of equipment) to conduct a randomised trial of primary HPV screening from Roche Molecular Systems. Further details of The BMJ policy on financial interests is here: https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf.
Comment on
-
Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.BMJ. 2019 Apr 3;365:l1161. doi: 10.1136/bmj.l1161. BMJ. 2019. PMID: 30944092 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources